New
FOR IMMEDIATE RELEASE
New York, New York, September 10, 2024 – The Vitiligo Research Foundation (VR Foundation) announces a strategic partnership with Skinopathy to provide the vitiligo community with the most advanced AI technology available to dermatology patients today.
Vitiligo, an incurable autoimmune disorder affecting nearly 100 million people globally, causes progressive white skin lesions and impacts other vital organs and mental health. With misdiagnosis rates up to 40% and treatment delays common, many patients miss opportunities for effective disease management. The VR Foundation and Skinopathy aim to address these challenges through advanced tele-dermatology and AI tools.
"Skinopathy's best-in-the-class AI technology can identify common types of vitiligo from a selfie and track treatment progress, providing optimal recommendations to both dermatologists and patients," says Yan Valle, Executive Director of the VR Foundation. "We're partnering to develop the ultimate AI assistant for vitiligo."
The partnership will empower vitiligo patients through:
- Early diagnosis of new onset or relapse
- Personalized care recommendations
- Treatment monitoring via a personal journal
- Access to the latest news, clinical trials, and products
Dr. Adriana Cruz, host of the 2024 World Vitiligo Day conference, praises the technology: "It provides a holistic approach to managing a person's vitiligo journey from start to finish."
Dr. Torello Lotti, Chair of the VR Foundation's Scientific Committee, adds: "Skinopathy's platforms can significantly improve the lives of those suffering from vitiligo's psychological impact."
With over 2/3 of vitiligo patients not receiving professional treatment, the VR Foundation and Skinopathy aim to provide millions with access to cutting-edge medical technologies for better condition management.
About the Vitiligo Research Foundation:
The VR Foundation is a NYC-based non-profit dedicated to advancing vitiligo research, awareness, and support since 2010.
Website: www.vrfoundation.org
Media Contact:
Yan Valle, VR Foundation
646-327-8169
yan@vrfoundation.org
About Skinopathy:
Skinopathy is an award-winning Canadian medical AI company providing digital health tools for effective skin condition management.
Website: www.skinopathy.com
Media Contact:
Richard Pietro, Skinopathy
647-760-1540
richard@skinopathy.com
FAQOther Questions
- Does vitiligo increase the risk of skin cancer?
No, it does not. Despite common misconceptions, people with vitiligo are actually at a lower risk of developing skin cancer, including both nonmelanoma skin cancer (NMSC) and ma...
- PTSD in Vitiligo?
Living with vitiligo often involves dealing with more than just skin changes. Many people with vitiligo face discrimination, social stigma, and isolation, which can lead to lowe...
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.